Introducing the Nucleus 8 Sound Processor | Cochlear скачать в хорошем качестве

Introducing the Nucleus 8 Sound Processor | Cochlear

Introducing the all-new Nucleus 8 Sound Processor, the smallest and lightest behind-the-ear hearing device from Cochlear.* The Nucleus 8 Sound Processor is ready for next generation Bluetooth® LE (Low Energy) technology, so you will be able to connect directly to what’s being broadcast around you, like public televisions or your local cinema.^# Learn more here https://www.cochlear.com/au/nucleus8 #cochlearimplant #cochlear #bluetooth #Nucleus ^ As Bluetooth LE Audio compatible devices become available, a sound processor firmware update may be required to use certain features. Auracast™ broadcast audio capability is subject to third party adaption of the Auracast protocol. Compared to Nucleus 6 and Nucleus 7 sound processors. References 1. Cochlear Limited. D1190805, Processor Size Comparison. May 2022. 2. Hunn N. Introducing Bluetooth® LE Audio [Internet]. [cited 2022 Jan]. Available from: https://www.bluetooth.com/learn-about... 3. Cochlear Limited. D1631375 Nucleus 8 Sound Processor Product Definition. 4. A Technical Overview of LC3 [Internet]. Bluetooth® Technology Website. [cited 2022 Feb 28]. Available from: https://www.bluetooth.com/blog/a-tech... In Australia, Cochlear™ Nucleus® implant systems are intended for the treatment of moderately severe to profound hearing loss. In Australia, Baha® bone conduction implant systems are intended for the treatment of moderate to profound hearing loss. In Australia, the Cochlear™ Osia® System is indicated for patients with conductive, mixed hearing loss and single-sided sensorineural deafness (SSD) aged 10 years and above with up to 55 decibels sensorineural hearing loss. Patients should have sufficient bone quality and quantity to support successful implant placement. Surgery is required to use this product. Any surgical procedure carries risk. For Cochlear™ Nucleus®, Osia® and Baha® systems: This product is not available for purchase by the general public. For information on funding and reimbursement please contact your health care professional.